New hepatitis C drug! Gileadji III Epclusa has been approved by Japan for the treatment of hepatitis C type 1-6

, a hepatitis C treatment giant, recently announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Epclusa (sofosbuvir 400mg/velpatasvir 100mg) for treatment: (1) adults infected with chronic hepatitis C virus (HCV) accompanied by uncompensated cirrhosis of the liver, and (2) people infected with chronic HCV without cirrhosis or compensation for cirrhosis of the liver who have received direct antiviral therapy (DAA).
, so far, no treatment options have been approved in Japan for patients with compromised cirrhosis, and there are limited treatment options for patients with hepatitis C who have received DAA treatment. Epclusa's approval will provide a new treatment option for these two groups of retrendable hepatitis C.
Dr. John McHutchison, Chief Scientific Officer and Head of Research and Development at Gilead Sciences, said, "Gilead continues to develop new HCV therapies to help all HCV patients get a cure and ultimately to help eradicate hepatitis C disease worldwide." In Japan, patients with hepatitis C with unpaid cirrhosis or those who have previously received hepatitis C medication but have not been cured have few treatment options. We are pleased to launch Epclusa in Japan to meet the significant medical needs that exist in this market.
Epclusa is a daily pan-genotype hepatitis C cocktail therapy developed for the treatment of all 6 genotypes (GT-1, -2, -3, -4, -5, -6) of hepatitis C patients. The cocktail is made up of Gilead's listed hepatitis C star drug Sofosbuvir and another antiviral drug, velpasvir. Among them, sofosbuvir is a nucleoside analogogen polymerase inhibitor, velpatasvir is a generic genotype NS5A inhibitor. In the United States, Epclusa is also approved for use with hepatitis C and AIDS (HCV/HIV) co-infected persons.: 3 generations of hepatitis C products are approved for listing in China
In the Chinese market, Gilead's 3 generations of hepatitis C products have been approved: (1) September 25, 2017, Sovaldi (Sovaldi, Common name: Sophosbuvir, sofosbuvir, 400mg tablets) approved, combined with other drugs to treat full genotype (type 1-6) hepatitis C virus infection in adults and adolescents aged 12-18 years, This approval makes Sovoaldi the first hepatitis C treatment drug to be officially approved by Gilead in China; Vipatave, sofosbuvir/velpatasvir, 400mg/100mg tablets) approved for the treatment of adult infections with genotype 1-6, hybrid and unknown chronic HCV. Epclusa became China's first pan-gene HCV single tablet solution. (3) On December 4, 2018, Harvoni (Xia Fanning, ledipasvir/sofosbuvir, 90mg/sophosphobwe 400mg) was approved for the treatment of adults infected with chronic hepatitis C virus (HCV) type 1-6 and adolescents aged 12-18 years.
of the above three hepatitis C drugs, Sovaldi is commonly known internationally as "Ji Generation", Harvoni is commonly known internationally as "Ji II" and Epclusa is commonly known internationally as "Ji III". Notably, three U.S. drug labels come with a black-box warning that the drug may be at risk of reactivation of hepatitis B virus (HBV) in patients with hepatitis C/B (HCV/HBV) co-infection. (Bio Valley)